{"id":"W2944392072","doi":"10.1186/s40425-019-0541-0","title":"An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vector Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute; Ontario Ministry of Research, Innovation and Science; Canada Research Chairs; Government of Ontario; Ontario Institute for Cancer Research; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Internal medicine; Immunophenotyping; Oncology; Immune system; CD8; Tumor-infiltrating lymphocytes; Interim analysis; Clinical trial; Immunotherapy; Immunology; Antigen","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003830035,0.0002344697,0.0005841233,0.0002291671,0.0001469561,0.00003333571,0.0003042168,0.0001266162,0.001447315],"category_scores_gemma":[0.0003089126,0.0001424808,0.0003309935,0.0002833514,0.0001803749,0.0001576424,0.00001248071,0.0003539011,0.000001836047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003469537,"about_ca_system_score_gemma":0.0009894568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001315163,"about_ca_topic_score_gemma":0.000009164392,"domain_scores_codex":[0.9969862,0.0006248405,0.001094076,0.0002652673,0.0007888728,0.0002407703],"domain_scores_gemma":[0.9970245,0.0003031775,0.001084665,0.0007193447,0.0007847266,0.00008354476],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2147262,0.002260303,0.003188032,0.00002629038,0.001334224,0.00001479524,0.001964664,0.00004624351,0.7282369,0.00001491138,0.0004599111,0.04772749],"study_design_scores_gemma":[0.1698098,0.1545053,0.2574072,0.001774628,0.0009183162,0.001030512,0.008747362,0.001660047,0.3591464,0.0004725764,0.04374772,0.0007801008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991771,0.003256127,0.00002358725,0.001516994,0.0009202978,0.002366542,0.0000218943,0.00002000378,0.0001035803],"genre_scores_gemma":[0.9977567,0.000556526,0.00005333478,0.001038805,0.0001142798,0.0001688672,0.00001046914,0.00004341064,0.0002576394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3690905,"threshold_uncertainty_score":0.9994655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1028992372457835,"score_gpt":0.4450525707470737,"score_spread":0.3421533335012902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}